Altrubio Inc.

Altrubio Inc. company information, Employees & Contact Information

Updated May 2026

Quick answer

Altrubio Inc. is a Biotechnology Research company and founded in 2020. It has approximately 30 employees on record. Contact data was last refreshed in May 2026. Find Altrubio Inc.'s verified employee emails, phone numbers, headquarters address, and key decision makers below.

Explore related pages

Related company profiles:

AltruBio is developing first-in-class immune-modulators targeting diseases of #immunology and #inflammation. Its world-class global team brings a breadth of expertise in immunology and drug development that will help advance their biologic treatments to patients. Learn more at https://www.altrubio.com/altrubio/en

Company Details

Employees
30
Founded
-
Address
505 Montgomery St,
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
jobs.
HQ
San Francisco, California
Looking for a particular Altrubio Inc. employee's phone or email?

Altrubio Inc. Questions

News

VC-Funded Life Sciences Companies in the Bay Area - The Business Journals

VC-Funded Life Sciences Companies in the Bay Area The Business Journals

AltruBio Announces Formation of Scientific Advisory Board - BioSpace

AltruBio Announces Formation of Scientific Advisory Board BioSpace

AltruBio Secures up to $225M Oversubscribed Series B Financing to Advance the Clinical Development of Novel Immune Checkpoint Enhancer Program - Yahoo Finance

AltruBio Secures up to $225M Oversubscribed Series B Financing to Advance the Clinical Development of Novel Immune Checkpoint Enhancer Program Yahoo Finance

AltruBio lands up to $225M after shift to immune drug research - BioPharma Dive

AltruBio lands up to $225M after shift to immune drug research BioPharma Dive

AltruBio raises $225 million to develop ulcerative colitis drug and other immune checkpoint enhancers - statnews.com

AltruBio raises $225 million to develop ulcerative colitis drug and other immune checkpoint enhancers statnews.com

AltruBio, after tweaking checkpoint drug, raises $225M for midphase ulcerative colitis program - Fierce Biotech

AltruBio, after tweaking checkpoint drug, raises $225M for midphase ulcerative colitis program Fierce Biotech

AltruBio Raises $63 Million Series A Round To Continue Its Company Transformation - GlobeNewswire

AltruBio Raises $63 Million Series A Round To Continue Its Company Transformation GlobeNewswire

AltruBio doses first subject in Phase I ulcerative colitis therapy trial - Clinical Trials Arena

AltruBio doses first subject in Phase I ulcerative colitis therapy trial Clinical Trials Arena

Investment Surges in Immunology Boost AltruBio’s Prospects - The Healthcare Technology Report.

Investment Surges in Immunology Boost AltruBio’s Prospects The Healthcare Technology Report.

AltruBio: $225 Million Raised To Develop Novel Therapeutics For Treating Immunological Diseases With Unmet Medical Needs - Pulse 2.0

AltruBio: $225 Million Raised To Develop Novel Therapeutics For Treating Immunological Diseases With Unmet Medical Needs Pulse 2.0

AltruBio Raises $225M in Series B to Advance Ulcerative Colitis Candidate - BioSpace

AltruBio Raises $225M in Series B to Advance Ulcerative Colitis Candidate BioSpace

The Week’s 10 Biggest Funding Rounds: Scale AI’s Massive $1B Deal Leads Slower Week - Crunchbase News

The Week’s 10 Biggest Funding Rounds: Scale AI’s Massive $1B Deal Leads Slower Week Crunchbase News

New name, new board, new focus: AltruBio relaunches with $63M series A - Fierce Biotech

New name, new board, new focus: AltruBio relaunches with $63M series A Fierce Biotech

Former Bayer, Genentech exec's biotech raises $225 million to target ulcerative colitis - San Francisco Business Times - The Business Journals

Former Bayer, Genentech exec's biotech raises $225 million to target ulcerative colitis - San Francisco Business Times The Business Journals

AltruBio snags a CMO after pivot from oncology to immunology - Fierce Biotech

AltruBio snags a CMO after pivot from oncology to immunology Fierce Biotech

The Bay Area's most VC-funded life sciences companies by equity raised in 2024 - San Francisco Business Times - The Business Journals

The Bay Area's most VC-funded life sciences companies by equity raised in 2024 - San Francisco Business Times The Business Journals

Three Influential Women in Biopharma Explain How to Break the Executive Barrier - BioSpace

Three Influential Women in Biopharma Explain How to Break the Executive Barrier BioSpace

Chutes & Ladders—AltruBio snags new CMO with resume at Sublimity, Ardea, Amgen and Abbott - Fierce Biotech

Chutes & Ladders—AltruBio snags new CMO with resume at Sublimity, Ardea, Amgen and Abbott Fierce Biotech

Top Altrubio Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant